Business
InMed Continues to Make Significant Strides on Biosynthesis Program Development
InMed Continues to Make Significant Strides on Biosynthesis Program Development Ca...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Continues to Make Significant Strides on Biosynthesis Program Development\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Sept. 25, 2017\n\n\n\nCSE: INOTCQB: IMLFF\n\n\n\nVANCOUVER, Sept. 25, 2017 /CNW/ - InMed Pharmaceuticals, Inc. (\"InMed\" or the \"Company\") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today an update to its investors and stakeholders on the significant advancements in its proprietary technology for the microbial biosynthesis of cannabinoids. \n\n\n \n \n\n \nInMed has successfully demonstrated that it can selectively produce all four \"gateway\" cannabinoids using genetically engineered microorganisms. These molecules can be functionalized further to produce any of the 90+ \"downstream\" cannabinoids found naturally in the cannabis plant. The company is actively employing this production chassis to synthesize compounds for its pharmaceutical research programs.\n\nEric A. Adams, President & CEO states, \"Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed. We are dedicating substantial resources to this project and have retained key individuals as we transition into the advanced pilot and to the commercialization phases of development. The breadth and depth of our patents, currently either submitted or being prepared for submission, will provide significant protection to the entire process.\"\n\nInMed's biosynthesis program has resulted in two significant \"firsts\":\n\n\nnew metabolic pathway for manufacturing the terpenoid family of cannabinoid precursors that is much more robust than other microbial expression tested by InMed\nfirst ever production of any fully-assembled 'downstream' cannabinoids in E. coli, beginning with genetic material to produce all precursors, enzymes, and synthases\n\nMicroorganisms do not naturally produce cannabinoids. However, utilizing genetic engineering to modify their inner workings, InMed ha...